In the same model, intraperitoneal injection of CCR2 antagonist RS504393 starting at day 3 after TAC surgery for 4 days blocked cardiac macrophage accumulation, reduced cardiac vascular cell adhesion protein 1 (VCAM-1) expression, reduced HW/TL and cardiac fibrosis, and improved cardiac hypertrophy and cardiac function. This evidence concerns the gene CCR2 and persistent truncus arteriosus.